Following after are RSV vaccines from Johnson & Johnson as well ... It will compete with Sobi's Synagis (palivizumab), an antibody originated by AZ, which is dosed once a month.

One dose of any of these three vaccines will complete your vaccination. The monoclonal antibodies palivizumab (Synagis) and nirsevimab (Beyfortus), are recommended for infants who are too young ...

A similar antibody treatment injection, called Synagis, has been available for infants at especially high-risk for RSV since 1998. You can get an RSV vaccine from your physician or local retail ...

Merck, aiming for pediatric use, would still join a wider market with the three new vaccines made by Pfizer, GSK and Moderna, as well as earlier monoclonal antibodies like Synagis and Beyfortus.

Since the US Food and Drug Administration’s 1998 approval of MedImmune’s Synagis (palivizumab ... Prophylactic vaccination mimics an infection and achieves similar protection.

Beyfortus is expected to eventually supplant Synagis, although Sobi’s antibody isn’t its main competition. That will come if the FDA approves an RSV vaccine developed by Pfizer that is given ...

The development of RSV vaccines presents specific challenges, and their clinical use is currently a distant prospect. Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal ...